Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 1
2002 1
2003 1
2004 1
2012 1
2015 1
2016 1
2017 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.
Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. Karuturi M, et al. Among authors: hutto t. Leuk Lymphoma. 2016 Feb;57(2):445-447. doi: 10.3109/10428194.2015.1032966. Epub 2015 Mar 25. Leuk Lymphoma. 2016. PMID: 25804933 Free PMC article. No abstract available.
Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Johansen M, Zukowski T, Hoff PM, Newman RA, Ni D, Hutto T, Abbruzzeese J, Berghorn E, Hausheer F, Madden T. Johansen M, et al. Among authors: hutto t. Cancer Chemother Pharmacol. 2004 May;53(5):370-6. doi: 10.1007/s00280-003-0743-4. Epub 2003 Dec 18. Cancer Chemother Pharmacol. 2004. PMID: 15060739 Clinical Trial.